Texas A&M Football

Charean Williams projects where Aggies could land in 2026 NFL Draft

The 2026 NFL Draft will begin on Thursday in Pittsburgh, PA, with a whole bunch of Aggies hoping to hear their name called. ProFootballTalk's Charean Williams joined Tuesday's edition of TexAgs Live to speak on which Ags could be first-rounders.
By David Nuño
April 21, 2026
10k Views
Discuss
Story Poster
Photo by Callie Garner, TexAgs
Free Preview
Watch the full version by becoming a Premium subscriber.
Try Premium for $1
No Thanks
Trial available for new subscribers only.

Key notes from Charean Williams interview

  • It was awesome. I was on the edge of my seat watching the women's golf team play Texas and beat them. It’s been a fun couple of weeks watching the Aggies win in a lot of stuff. It’s a great day to be an Aggie, and it’s felt like that for a couple of weeks.
     
  • I didn't see any of the spring game. I think the Daymion Sanford injury was probably the biggest thing.
To watch the full version of this video feature, you must be a TexAgs Premium subscriber.
Try Premium for $1
See Subscription Benefits →
Trial only available to users who have never subscribed or participated in a previous trial
Discuss
Tags
TexAgs Live Charean Williams NFL Draft TexAgs Live Feature David Bailey Ty Simpson Jermod McCoy Nnamdi Madubuike 2026 NFL Draft Le'Veon Moss Chase Bisontis KC Concepcion
Show All
Daymion Sanford Cashius Howell Football Texas A&M 2026
More Football
See All →
Mark Nabou Jr. expects A&M's offensive front to be 'really good'
By David Nuño
College graduate Trovon Baugh wants to give back
By David Nuño
TexAgs Rewind (5/11)
By TexAgs Live
Lunch with Liucci: Billy Liucci joins TexAgs Live (Monday, May 11)
By Billy Liucci
Discussion from...

Charean Williams projects where Aggies could land in 2026 NFL Draft

8,916 Views | 0 Replies | Last: 20 days ago by David Nuño
There are not any replies to this post yet.
Refresh
Page 1 of 1
 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.